Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
NCPD Article
Essentials

Platelet Refractoriness: Examining Associated Morbidity and Mortality

Sijimol Mathew
CJON 2021, 25(1), 89-92 DOI: 10.1188/21.CJON.89-92

Platelet refractoriness is defined as the failure of platelets to show adequate increment after platelet transfusion. Platelets are important to the normal clotting and hemostasis process in the prevention of bleeding. Platelet refractoriness is a significant clinical concern because of resulting hemorrhagic emergencies, increased length of hospital stays, higher inpatient costs, and decreased survival. As part of the healthcare team, oncology nurses play a crucial role in early detection and using evidence-based management strategies for platelet refractoriness to limit the potential for associated morbidity and mortality.

AT A GLANCE

  • Platelet refractoriness is a significant clinical concern related to the onset of hemorrhagic emergencies.
  • Corrected count increment calculation after transfusion is recommended to help monitor and manage patients with platelet refractoriness.
  • Early detection of immune-mediated causes enables appropriate platelet transfusions to achieve a good increment in the recipient’s platelet count.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or